The european post-marketing observational serdolectρ (EPOS) project: Increasing our understanding of schizophrenia therapy

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Wehnert, Allan ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Adverse events; Epidemiology; Observational study; Schizophrenia; Sertindole

Indexed keywords

SERTINDOLE;

DRUG MARKETING; DRUG SAFETY; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COHORT STUDIES; EUROPE; HUMANS; IMIDAZOLES; INDOLES; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0031777576     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199802002-00005     Document Type: Review

References (17)

1. Awad AG (1992). Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 43:262-265.
2. Baldessarini RJ, Huston-Lyons D, Campbell A (1992). Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160 (suppl 17):12-16.
3. Black D (1988). Mortality in schizophrenia: the Iowa record linkage study: a comparison with general population mortality. Psychosomatics 29:55-59.
4. Bunney BS (1984). Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 7:212-215.
5. Daniel D, Schmitz P, Staser J, Holgate K, Sebree T, Cravets M (1996).Two-open label, long-term safety studies of sertindole [abstract NR544]. In: 149th Annual Meeting of the American Psychiatric Association, New York, NY, 4-9 May 1996. Washington (DC): American Psychiatric Association. p. 218.
6. Domeney AM, Arnt J, Costall B (1994). Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 31:175-185.
7. H Lundbeck A/S (1996). Summary of product characteristics: Serdolect®, sertindole. Copenhagen: H Lundbeck A/S.
8. 2 and alpha one receptors. J Neural Transm 89:61-69.
9. van Kammen PD, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124:168-175.
10. Kerwin R (1993). Adverse reaction reporting and new antipsychotics. Lancet 342:1440.
11. Meltzer HY, Nash FJ (1991). Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604.
12. Sánchez C, Arnt J, Dragsted N (1992). Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
13. Skarsfeldt T (1992). Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33.
14. Trimble MR, Zarifian E ( 1985). Psychopharmacology of the limbic system. Monogr. no. 5, British Association of Psychology. Oxford: Oxford University Press.
15. Wood S (1991). Postmarketing surveillance: viewpoint from a regulatory authority. Drug Information J 25:191-195.
16. Zborowski J, Schmitz P, Staser J, O'Neil J, Giles K, Wallin B, et al. (1995). Efficacy and safely of sertindole in a trial of schizophrenic patients [abstract]. In: 49th Annual Convention of the Society of Biological Psychiatry, Miami, FL, May 1995. New York: Society of Biological Psychiatry.
17. Zimbroff D, Kane J, Tamminga C, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.